U.S. markets close in 1 hour 14 minutes
  • S&P 500

    4,511.97
    -65.13 (-1.42%)
     
  • Dow 30

    34,390.13
    -249.66 (-0.72%)
     
  • Nasdaq

    14,993.13
    -388.19 (-2.52%)
     
  • Russell 2000

    2,152.82
    -53.52 (-2.43%)
     
  • Crude Oil

    66.12
    -0.38 (-0.57%)
     
  • Gold

    1,784.00
    +21.30 (+1.21%)
     
  • Silver

    22.52
    +0.21 (+0.94%)
     
  • EUR/USD

    1.1320
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.3530
    -0.0950 (-6.56%)
     
  • GBP/USD

    1.3240
    -0.0062 (-0.47%)
     
  • USD/JPY

    112.6580
    -0.5510 (-0.49%)
     
  • BTC-USD

    54,137.69
    -2,579.33 (-4.55%)
     
  • CMC Crypto 200

    1,365.20
    -76.56 (-5.31%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

STAMFORD, Conn., Jan. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020 at 1:30 p.m. Pacific Standard Time. A breakout question and answer session will immediately follow the presentation.

To access the live webcast of SpringWorks’ presentation, please visit the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for approximately 30 days following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, please visit www.springworkstx.com.

Follow SpringWorks Therapeutics on social media: @SpringWorksTx and LinkedIn.

Contact:
Kim Diamond
Phone: 646-661-1255
Email: kdiamond@springworkstx.com